Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2460

1.

Chronic cough in a patient with stable ulcerative colitis: a rare but important extraintestinal manifestation of inflammatory bowel disease.

Chad T, Brown J.

BMJ Case Rep. 2019 Jan 14;12(1). pii: bcr-2018-227066. doi: 10.1136/bcr-2018-227066.

PMID:
30642857
2.

Optimising infliximab induction dosing for patients with ulcerative colitis.

Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, Bouillon T.

Br J Clin Pharmacol. 2019 Jan 11. doi: 10.1111/bcp.13859. [Epub ahead of print]

PMID:
30634202
3.

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis.

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R.

Clin Gastroenterol Hepatol. 2019 Jan 5. pii: S1542-3565(19)30013-8. doi: 10.1016/j.cgh.2018.12.040. [Epub ahead of print]

4.

Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response.

Haberman Y, Karns R, Dexheimer PJ, Schirmer M, Somekh J, Jurickova I, Braun T, Novak E, Bauman L, Collins MH, Mo A, Rosen MJ, Bonkowski E, Gotman N, Marquis A, Nistel M, Rufo PA, Baker SS, Sauer CG, Markowitz J, Pfefferkorn MD, Rosh JR, Boyle BM, Mack DR, Baldassano RN, Shah S, Leleiko NS, Heyman MB, Grifiths AM, Patel AS, Noe JD, Aronow BJ, Kugathasan S, Walters TD, Gibson G, Thomas SD, Mollen K, Shen-Orr S, Huttenhower C, Xavier RJ, Hyams JS, Denson LA.

Nat Commun. 2019 Jan 3;10(1):38. doi: 10.1038/s41467-018-07841-3.

5.

American Gastroenterological Association Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Singh S, Feuerstein JD, Binion DG, Tremaine WJ.

Gastroenterology. 2018 Dec 18. pii: S0016-5085(18)35406-4. doi: 10.1053/j.gastro.2018.12.008. [Epub ahead of print]

PMID:
30576642
6.

Incidence and clinical impact of perianal disease in patients with ulcerative colitis: A nationwide population-based study.

Song EM, Lee HS, Kim YJ, Oh EH, Ham NS, Kim J, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK.

J Gastroenterol Hepatol. 2018 Nov 22. doi: 10.1111/jgh.14555. [Epub ahead of print]

PMID:
30549125
7.

Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience.

Argyriou K, Samuel S, Moran GW.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):183-186. doi: 10.1097/MEG.0000000000001326.

PMID:
30499784
8.

Risk factors for postoperative infection after gastrointestinal surgery among adult patients with inflammatory bowel disease: Findings from a large observational US cohort study.

Liang H, Jiang B, Manne S, Lissoos T, Bennett D, Dolin P.

JGH Open. 2018 Aug 23;2(5):182-190. doi: 10.1002/jgh3.12072. eCollection 2018 Oct.

9.

A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial.

Del Hoyo J, Nos P, Faubel R, Muñoz D, Domínguez D, Bastida G, Valdivieso B, Correcher M, Aguas M.

J Med Internet Res. 2018 Nov 27;20(11):e11602. doi: 10.2196/11602.

10.
11.

Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.

Targownik LE, Benchimol EI, Bernstein CN, Singh H, Lix ML, Tennakoon A, Leung S, Aviña A, Coward S, Jones J, Kaplan G, Murthy SK, Nguyen GC, Peña-Sánchez JN.

Clin Gastroenterol Hepatol. 2018 Nov 15. pii: S1542-3565(18)31246-1. doi: 10.1016/j.cgh.2018.11.003. [Epub ahead of print]

PMID:
30448599
12.

Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.

Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T.

Gut. 2018 Nov 12. pii: gutjnl-2018-317021. doi: 10.1136/gutjnl-2018-317021. [Epub ahead of print]

PMID:
30420398
13.

Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.

Nishio M, Ishii Y, Hashimoto Y, Otake H, Ogashiwa T, Tsuda S, Yasuhara H, Saigusa Y, Kimura H, Maeda S, Kunisaki R.

Scand J Gastroenterol. 2018 Oct 24:1-9. doi: 10.1080/00365521.2018.1511825. [Epub ahead of print]

PMID:
30353757
14.

Rectal Lymphoid Follicle Aphthous Lesions Frequently Progress to Ulcerative Colitis with Proximal Extension.

Hayashi R, Ueno Y, Tanaka S, Wakai M, Kumada J, Fujita A, Nomura M, Oka S, Ito M, Chayama K.

Intern Med. 2018 Oct 17. doi: 10.2169/internalmedicine.1635-18. [Epub ahead of print]

15.

Development and validation of risk matrices concerning ulcerative colitis outcomes - Bayesian network analysis.

Magro F, Dias CC, Portela F, Miranda M, Fernandes S, Bernardo S, Ministro P, Lago P, Rosa I, Pita I, Correia L, Rodrigues PP; GEDII (Portuguese IBD Group).

J Crohns Colitis. 2018 Oct 17. doi: 10.1093/ecco-jcc/jjy168. [Epub ahead of print]

PMID:
30329032
16.

Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course.

Schirmer M, Denson L, Vlamakis H, Franzosa EA, Thomas S, Gotman NM, Rufo P, Baker SS, Sauer C, Markowitz J, Pfefferkorn M, Oliva-Hemker M, Rosh J, Otley A, Boyle B, Mack D, Baldassano R, Keljo D, LeLeiko N, Heyman M, Griffiths A, Patel AS, Noe J, Kugathasan S, Walters T, Huttenhower C, Hyams J, Xavier RJ.

Cell Host Microbe. 2018 Oct 10;24(4):600-610.e4. doi: 10.1016/j.chom.2018.09.009.

PMID:
30308161
17.

Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey.

Rodríguez-Lago I, Ferreiro-Iglesias R, Nos P, Gisbert JP; en representación del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).

Gastroenterol Hepatol. 2018 Oct 4. pii: S0210-5705(18)30251-6. doi: 10.1016/j.gastrohep.2018.09.002. [Epub ahead of print] English, Spanish.

PMID:
30293913
18.

Algorithms to facilitate shared decision making for the management of mild-to-moderate ulcerative colitis.

Jackson B, De Cruz P.

Expert Rev Gastroenterol Hepatol. 2018 Oct 4. doi: 10.1080/17474124.2018.1530109. [Epub ahead of print]

PMID:
30284911
19.

Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Solanky D, Pardi DS, Loftus EV Jr, Khanna S.

Inflamm Bowel Dis. 2018 Sep 26. doi: 10.1093/ibd/izy291. [Epub ahead of print]

PMID:
30260451
20.

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.

Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J.

BMC Gastroenterol. 2018 Sep 15;18(1):140. doi: 10.1186/s12876-018-0868-x.

Supplemental Content

Loading ...
Support Center